[Federal Register: November 2, 2004 (Volume 69, Number 211)]
[Notices]
[Page 63540-63541]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr02no04-68]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-04-0307]
Proposed Data Collections Submitted for Public Comment and
Recommendations
The Centers for Disease Control and Prevention (CDC) publishes a
list of information collection requests under review by the Office of
Management and Budget (OMB) in compliance with the Paperwork Reduction
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call
the CDC Reports Clearance Officer at (404) 498-1210 or send an e-mail
to omb@cdc.gov. Send written comments to CDC Desk Officer, Human
Resources and Housing Branch, New Executive Office Building, Room
10235, Washington, DC 20503 or by fax to (202) 395-6974. Written
comments should be received within 30 days of this notice.
Proposed Project
Gonococcal Isolate Surveillance Project (GISP), OMB No. 0920-0307--
Revision--National Center for HIV, STD, and TB Prevention (NCHSTP),
Centers for Disease Control and Prevention (CDC).
CDC is requesting a 3-year approval/with change for this project.
The objectives of GISP are to monitor trends in antimicrobial
susceptibility of strains of Neisseria gonorrhoeae in the U.S. and
characterize resistant isolates. GISP provides critical surveillance
for antimicrobial resistance, allowing for informed treatment
recommendations. This project began in 1986 as a voluntary surveillance
project and has involved 5 regional laboratories and 30 publicly-
funded, sexually transmitted disease (STD) clinics around the country.
The STD clinics submit up to 25 gonococcal isolates per month to the
regional laboratories, which measure susceptibility to a panel of
antibiotics. Limited demographic and clinical
[[Page 63541]]
information corresponding to the isolates are submitted directly by the
STD clinics to CDC.
During 1986-2003, GISP demonstrated the ability to effectively
achieve its objectives. The emergence, in the U.S., of resistance to
fluoroquinolones, commonly used therapies for gonorrhea, was identified
through GISP and makes ongoing surveillance critical. Emergence of
decreased susceptibility to fluoroquinolones among the men having sex
with men (MSM) population in the U.S. was also identified through GISP
in 2003. Data gathered through GISP were used to change the treatment
for gonorrhea for the MSM population in April 2004. There are no costs
to respondents other than their time. The estimated annualized burden
for this data collection is 8,142 hours.
------------------------------------------------------------------------
Number of Average
Number of responses burden per
Respondent respondents per response
respondent (in hours)
------------------------------------------------------------------------
Laboratory:
Form 2.................... 5 1368 1
Form 3.................... 5 48 12/60
Clinical personnel............ 30 228 11/60
------------------------------------------------------------------------
Dated: October 27, 2004.
B. Kathy Skipper,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. 04-24385 Filed 11-1-04; 8:45 am]
BILLING CODE 4163-18-P